好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characterizing Stair Ambulation, Functional Mobility, and Dual-tasking in Parkinson's Disease
Movement Disorders
P9 - Poster Session 9 (5:00 PM-6:00 PM)
17-011

To quantify dual-task interference (DTI) in individuals with Parkinson’s disease (PD) using a comprehensive functional mobility assessment platform.

Gait impairments in PD worsen under dual-task (DT) conditions, contributing to falls and reduced independence. Loss of striatal dopamine disrupts movement automaticity and increases cortical burden during complex motor tasks, such as stair ambulation under DT conditions. Stair ambulation poses elevated motor and cognitive demands but is rarely evaluated in traditional mobility assessments.

Twenty-three individuals with PD completed a mobility task using the Stair Ambulation and Functional Evaluation of Gait (Safe-Gait) system, which includes five phases: Ascent, Departure, Turn, Return, and Descent, providing a comprehensive assessment of stair ambulation, flat-ground walking, and turning. Participants performed the task under single-task (ST) and DT (serial 7s subtraction) conditions. Spatiotemporal data were collected, and DTI was calculated as the percent difference in segment duration between ST and DT conditions. Linear mixed models were used to estimate completion time differences between conditions.

Across all five phases, durations were significantly longer under DT conditions compared to ST (p<0.05). Average DTI for each phase was: Return - 22%, Departure - 20%, Ascent - 19%, Descent - 14%, and Turn - 13%, with an 18% increase in overall trial time under DT conditions.

The Safe-Gait system captured clinically relevant DTI across various functional mobility domains, including stair ambulation and turning. Data from robust assessment tools like Safe-Gait can reveal consequential gait impairments that may be missed by traditional assessments. This platform offers a promising tool for ecologically valid evaluation of mobility impairment in PD and provides data that can be leveraged to inform clinical decision-making and improve patient outcomes.

Authors/Disclosures
John G. Gardner
PRESENTER
Mr. Gardner has nothing to disclose.
Colin Waltz, BS Mr. Waltz has nothing to disclose.
Hailey E. Zimmerman Mrs. Zimmerman has received personal compensation for serving as an employee of Renew Biotechnologies.
Kelly E. Jones, PhD Dr. Jones has nothing to disclose.
Jay L. Alberts, PhD (Cleveland Clinic) Dr. Alberts has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ceraxis. Dr. Alberts has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ceraxis. The institution of Dr. Alberts has received research support from NIH. The institution of Dr. Alberts has received research support from Department of Defense. The institution of Dr. Alberts has received research support from Michael J. Fox Foundation. Dr. Alberts has received intellectual property interests from a discovery or technology relating to health care. Dr. Alberts has received personal compensation in the range of $500-$4,999 for serving as a Member, Health and Wellness Council with Peloton Interactive.